Heart Failure, Diastolic
Conditions
Brief summary
A 35-week, single-center, prospective, double-blind, controlled, randomized, 2x2 crossover, interventional Phase II study, investigating the effect of treatment with dapagliflozin 10mg od on Left Ventricular distensibility in patients with early HFpEF.
Interventions
DRUGDapagliflozin
10mg od
DRUGPlacebo
Placebo
Sponsors
AstraZeneca
Mariëlle Scheffer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years at time of screening 2. Symptomatic chronic heart failure patients with diagnosis of heart failure and: * NYHA class II-IV * Preserved systolic Left Ventricular (LV) function, defined by: LV Ejection Fraction (LVEF) ≥ 50% and LV end-diastolic volume index \<97 ml/m2 * Evidence of diastolic LV dysfunction and at least 1 out of the 5 following additional criteria: 1. H2FPEF score ≥ 6; 2. HFA-PEFF score ≥ 5; 3. Pulmonary capillary wedge pressure \> 15 mmHg at rest or \> 25 mmHg with exercise assessed with right heart catheterization; 3. Cardiac MRI T1 derived extracellular volume \<29% at screening 4. Oral diuretics, if prescribed to the patient according to local guidelines and at the discretion of the investigator, should be stable for at least 1 week prior to baseline visit 5. Signed and dated written informed consent in accordance with GCP and local legislation prior to admission to the trial
Exclusion criteria
1. Reduced systolic LV function (LVEF \< 50%), measured at any time point in the history of the patient 2. Obstructive coronary artery disease with evidence of ischemia 3. Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 90 days prior to screening visit 4. More than mild valve stenosis 5. More than moderate aortic and/or mitral valve regurgitation 6. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. hemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (stress cardiomyopathy), hypertrophic (obstructive) cardiomyopathy or known pericardial constriction 7. History of mitral valve repair or replacement 8. Atrial fibrillation or atrial flutter with a resting heart rate \> 110 bpm at screening 9. Acute decompensation that requires intravenous loop diuretics 10. Systolic blood pressure ≥ 180 mmHg. If SBP \> 150 mmHg and \< 180 mmHg, the patient should be receiving at least 3 antihypertensive drugs at screening or baseline visit 11. Symptomatic hypotension and/or a SBP \< 100 mmHg at screening or baseline visit 12. Impaired renal function, defined as eGFR \< 30 ml/min/1.73 m2 13. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3x upper limit of normal or history of cirrhosis with evidence of portal hypertension 14. Hemoglobin \< 9 g/dl at screening 15. Chronic obstructive pulmonary disease, more than GOLD class 2 16. Pulmonary function test with FEV1/FVC \< 80% 17. Primary pulmonary arterial hypertension 18. Type 1 Diabetes Mellitus 19. History of ketoacidosis 20. Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or low risk prostate cancer (biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) 21. Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor within 3 months prior to screening visit. Discontinuation of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor for the purposes of study enrolment is not permitted 22. Pregnancy or lactation 23. Any (clinical) condition that, in the investigator's opinion, would jeopardize patients safety while participating in this trial, or may prevent the patient from adhering to the trial protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular (LV) e' | 13 weeks | echocardiographically measured |
| E/e'/LV end-diastolic volume index | 13 weeks | echocardiographically measured |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Left atrial volume | 13 weeks | Echocardiographically derived volume |
| Kansas City Cardiomyopathy Questionnaire | 13 weeks | — |
| Left atrial function | 13 weeks | Echocardiographically derived strain analysis, resevoir, conduit and booster pump function |
| Diastolic parameters | 13 weeks | Echocardiographically derived function, filling and compliance of Left Ventricular |
| 6-minute walk test | 13 weeks | — |
Countries
Netherlands
Contacts
Primary ContactMarielle Scheffer, MD
Outcome results
None listed